Desenvolvimento de potenciais inibidores de ALDH1A3: um alvo potencial no combate a células-tronco de glioblastoma

Abstract

Glioblastoma is the most common, aggressive, and lethal type of brain tumor. Few treatments exist and the median survival period is less than 15 months after diagnosis. The permanence of subpopulations of glioma stem cells (GSCs) after treatments is a recent discovery that explains the high frequency of recurrences and metastases of this type of tumor. Aldehyde dehydrogenase family 1 member A3 (ALDH1A3) is an enzyme overexpressed in GSCs that has seen used as a biomarker and has been also pointed out as a potential pharmacological target for a selective and personalized therapy of Glioblastoma aiming at the elimination of tumor stem cells. In this context, the monoterpene citral (3,7-dimethyl-2,6-octadienal), presents itself as a promising natural product, as it can inhibit ALDH1A3.